Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Depreciation & Amortization (CF) (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $91000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 139.47% to $91000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $366000.0, a 297.83% increase, with the full-year FY2025 number at $366000.0, up 297.83% from a year prior.
  • Depreciation & Amortization (CF) was $91000.0 for Q4 2025 at Day One Biopharmaceuticals, up from $90000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $94000.0 in Q1 2025 to a low of $6000.0 in Q1 2022.
  • A 4-year average of $34812.5 and a median of $15500.0 in 2022 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): plummeted 69.44% in 2023, then soared 506.67% in 2025.
  • Day One Biopharmaceuticals' Depreciation & Amortization (CF) stood at $15000.0 in 2022, then decreased by 13.33% to $13000.0 in 2023, then surged by 192.31% to $38000.0 in 2024, then surged by 139.47% to $91000.0 in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Depreciation & Amortization (CF) are $91000.0 (Q4 2025), $90000.0 (Q3 2025), and $91000.0 (Q2 2025).